Velpatasvir, Hepatitis C protease inhibitor (TBI4931)

Description

Product Details

Formal Name: Methyl [(2S)-1-[(2S,5S)-2-[9-[2-[(2S,4S)-1-[(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl]-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

Alternate Names: GS-5816

Molecular Formula: C₄₉H₅₄N₈O₈

Formula Weight: 883

CAS Number: 1377049-84-7

Purity: >98%

Formulation: Powder

Solubility: Soluble in DMSO (up to 25 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.

Applications

Hepatitis C protease inhibitor

Functions

Velpatasvir is an extremely potent pan-genotypic hepatitis C virus (HCV) NS5A inhibitor. It is a component of Epclusa® and Vosevi®, two clinically useful medications with 98% and 97%, respectively, cure rates for HCV. It displayed EC50’s for GTs 1-4, 6a ranging from 6-16 pM, GT5a at 75 pM, and GT6e at 130 pM. Velpatasvir also displayed an excellent barrier to viral resistance. It has been shown in silico, that velpatasvir binds to the SARS-CoV-2 spike protein and may be a potential therapeutic.

Application Procedures

First dissolved in DMSO (up to 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.